Last Price
0.408
Today's Change
-0.29 (41.54%)
Day's Change
0.375 - 0.643
Trading Volume
9,962,175
Profile
VINC
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Ahmed M. Hamdy M.D. Dr. Ahmed M. Hamdy M.D.
Full Time Employees: 42 42
IPO Date: 2020-05-27 2020-05-27
CIK: 0001796129 0001796129
ISIN: US92731L1061 US92731L1061
CUSIP: 92731L106 92731L106
Beta: 1.17 1.17
Last Dividend: 0.00 0.00
Dcf Diff: -0.02 -0.02
Dcf: 0.49 0.49
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
Global Investors Are Hoarding Cash to Bet on Taiwan's AI Return
2
CEO Morning Brief
Trump Threatens 200% Tariff on Vehicles Imported From Mexico
3
CEO Morning Brief
Southeast Asian Scammers Stole Up to US$37b in 2023, UN Says
4
CEO Morning Brief
5
CEO Morning Brief
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
